Questions: The subject of this video, Martin Shkreli, was once the CEO of Retrophin, a biotechnology firm. Shkreli received a huge amount of negative press for increasing that company's drug prices by as much as 2,000% percent. Despite the controversy, it can be argued that this price hike benefited a shareholders b all stakeholders c doctors d patients

The answer is a shareholders

The price hike of the drug by as much as 2,000% would likely have increased the company's revenue and profits significantly. This, in turn, would benefit the shareholders as the value of their shares would increase due to higher profitability and potential dividends.

This option is less likely because while shareholders might benefit, other stakeholders such as patients and healthcare providers would face higher costs, which could lead to negative outcomes for them.

Doctors are unlikely to benefit directly from the price hike. In fact, they might face ethical dilemmas and challenges in prescribing a much more expensive drug to their patients.

Patients are the least likely to benefit from a significant price increase. Higher drug prices can lead to reduced access to necessary medications, financial strain, and overall negative health outcomes.